Efficacy of Long Term Plavix Therapy Post Angioplasty

Shiraz University of Medical Sciences

Status

Completed

Conditions

Percutaneous Coronary Intervention

Treatments

Drug: plavix

Study type

Interventional

Funder types

Other

Identifiers

NCT02327741

90-2348

Details and patient eligibility

About

1010 patients post stenting were enrolled to receive Plavix more than 12 months and less than that and rate of bleeding, complication and major cardiovascular adverse events ( MACE) were compared to evaluate safety and feasibility of long term Plavix therapy post stenting.

Full description

1010 patients from registry of angioplasty and stenting in Shiraz and Baghiatolah hospital were enrolled and long term Plavix therapy more than and less than 12 months were compared between two groups of patients prospectively and rate of major adverse cardiovascular events ( MACE) (death, myocardial infarction, cerebrovascular accidents and revascularization) and rate of bleeding were compared between 2 groups.Syntax score and American heart association ( AHA) score of coronary involvement were measured and MACE was compared to these scores.

Enrollment

1,010 patients

Sex

All

Ages

50 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

post stent ( lesion more than 70% and vessel more than 2.25 mm )

Exclusion criteria

allergy to acetylsalicylic acid or clopidogrel,
planned surgery within 24 months of percutaneous coronary intervention unless the dual antiplatelet therapy could be maintained throughout the perisurgical period
history of bleeding diathesis
major surgery within 15 days
active bleeding
previous stroke in the past 6 months
concomitant or foreseeable need for oral anticoagulation therapy
pregnancy, life expectancy <24 months, participation in another trial
inability to provide informed consent